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Abstract

The severity and complexity of depression can vary widely among individuals, thus
making single drug therapy ineffective in some cases. Taking this fact into account and
using a mouse model, we set on investigating the possibility of obtaining a synergism of
action between a classical tricyclic antidepressant that inhibits noradrenalin and serotonin
reuptake (doxepin), and a modern antidepressant that inhibits type-B monoamine oxidase
(selegiline). We measured the antidepressant effect using the forced swimming test and
the tail suspension test. We determined motor activity using the Activity Cage test. Our
results have shown that the antidepressant effect intensifies significantly in the animals
treated with both antidepressants simultaneously compared to those treated only with
doxepin. Furthermore, we observed that selegiline decreases the sedative effect of doxepin
in the Activity Cage test.
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✓ Selegiline plus doxepin double drug therapy increases significantly the antidepressant
effect
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✓ Selegiline plus doxepin double drug therapy prevents the sedative side effect of doxepin
administered as a single drug therapy
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Introduction
Depression is becoming a global problem due to the
stress caused by the adaptation difficulties that our highspeed way of life currently demands (1). Mood disorders
have been studied for decades and many theories have been
proposed to explain the cause of depression. The original
monoamine theory of depression suggested a direct
involvement of the adrenergic system in the onset of this
disorder (2). Later studies demonstrated a more complex
relationship
between
the
various
endogenous
neurotransmissions, suggesting an indirect role of the
adrenergic system in depression as it modulates the
function of other transmissions (3).
The first significant breakthrough in the treatment of
depressive disorders occurred 60 years ago with the
approval of imipramine, thus opening a path for an entire
class of drugs—tricyclic antidepressants—which act as
nonselective noradrenergic and serotoninergic reuptake
inhibitors (4). At the same time, compounds with other
mechanisms such as monoamine oxidase inhibitors,
enhanced the synaptic concentration of catecholamines and
achieved similar positive effects on the symptoms of
depression (5).
Selegiline was created by Joseph Knoll almost 60 years
ago and since then, it has been widely used for the
treatment of Parkinson`s disease in low doses, Alzheimer`s
disease, and major depression in higher doses (6).
Selegiline acts in 3 ways: it reduces dopamine
biotransformation through the inhibition of type B
monoamine oxidase; it inhibits the dopamine reuptake; and
it stimulates dopamine synthesis by blocking the
presynaptic dopamine receptors (7).
Although many therapeutic options are currently
available, there are still cases of antidepressant-resistant
depressions that require either new molecules (8-11) or
new approaches in managing these disorders (12). Given
that a new drug requires significant time and financial
resources, combining existent therapies may prove to be a
viable solution for treating complex atypical depressions.

Materials and Methods
A population of 70 white male NMRI mice having
reached maturity and weighing 34 ± 6g was supplied by the
rodent farm of “Carol Davila” University of Medicine and
Pharmacy. Animals were kept in cages for 24 hours
separately from other animals in order to reduce stress and
ensure a gradual transition to the new environment. Later,
they were housed in ventilated Plexiglas cages containing
groups of 10 individuals with free access to food and water.
Temperature and humidity were constant (21-23°C; 4555%) and monitored with an Eco Solar TFA30.1037
thermo-hygrometer.

262

All experiments were conducted in accordance with
the EU Directive 63/2010, Romanian Law 43/2014 and
Good Animal Practice Regulations. The protocol was
approved by the Bioethics Committee of “Carol Davila”
University.
The 70 mice were initially subjected to the Activity
cage test in order to configure the research groups.
Horizontal motor activity (Ugo Basile 47420 Multiple
Activity Cage unit) measured in 5-minute intervals was the
parameter used to identify individuals fit for this
experiment. After excluding individuals with extreme
responses, the 60 remaining mice were divided into 5
groups, each containing 12 animals, in such a manner that
the average responses and the standard deviations were as
similar as possible. Animals were then allowed two days
for acclimation in their new groups. On the day of the
experiment, each group was brought to the lab, two hours
before being treated, in order to allow adaptation to the new
environment where they were kept without food.
The 5 groups were treated as follows:
• Group I (control) – distilled water 0.1 ml/ 10g orally
• Group II – Doxepin 10 mg/ kg bw suspension 0.1%
orally
• Group III – Doxepin 15 mg/ kg bw suspension 0.15%
orally
• Group IV – Doxepin 10 mg/ kg bw suspension 0.1% +
Selegiline 2.5 mg/ kg bw suspension 0.25% orally
• Group V – Doxepin 15 mg/ kg bw suspension 0.15% +
Selegiline 5 mg/ kg bw suspension 0.5% orally
The substances used in this experiment were:
• Doxepin hydrochloride D4526 – Sigma Aldrich, USA
• Selegiline hydrochloride S0360000 – Sigma Aldrich,
USA
The tests were executed as follows:
• After one administration – the forced swimming test
• After 1 week of daily administrations (including the
testing day) – the tail suspension test and the Activity
cage test
• After 2 weeks of daily administrations (including the
testing day) – the tail suspension test and the Activity
cage test
Testing began one hour after the drugs were
administered.
All testing followed a specific protocol: in the testing
area, animals were kept in artificial light, without food.
Each individual was administered the treatment with an 8minute delay from the next one (5 minutes for the Activity
cage test; 6 minutes for the forced swimming and tail
suspension tests and 2 additional minutes to clean or
prepare the devices before testing another animal) so that
all of them could be tested after the same time interval from
the moment of receiving the treatment.

The antidepressant effect of associating doxepin and selegiline
Assessment of motor activity was conducted to assess
the effect on the central nervous system by recording the
horizontal and vertical movements of each mouse in the
Ugo Basile – Activity Cage. The animals were placed
individually in a corner of the cage and their movements
were recorded for 5 minutes by IR photoelectric cell
sensors (9, 13).
Assessment of immobility time of mice as a marker of
antidepressant activity was conducted in two tests:
• The forced swimming test (FST) consists of placing
each mouse in a glass cylinder (25 cm height, 30 cm
diameter) containing a 20 cm high column of water at a
temperature of 21 ± 1°C and recording the number of
seconds it rests afloat motionless during a 4-minute
interval after a prior 2-minute interval for
accommodation (14, 15, 16).
• The tail suspension test (TST) consists of suspending a
mouse by its own tail in such a manner that it cannot
touch neighboring surfaces nor escape. The animal is
maintained in this position for 6 minutes and in the last
4 minutes, the number of seconds spent motionless is
recorded (17, 18).

Statistics
For the statistical evaluation, the GraphPad Prism 5.0
software was used. This software analyzes populations
with Gaussian distribution using the Student t-test (for 2
groups) and the ANOVA test (for multiple groups). In case
of statistical significance in the ANOVA (p < 0.05), a
further post-test was conducted (Dunnett). The normality
of the distribution was determined using the D`Agostino –
Pearson test.
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The forced swimming test performed after the acute
administration revealed unsurprising results in the test
groups compared to the control group. Even though
statistical significance was not achieved, a higher decrease
in the immobilization time was noticed in the groups
treated with the combination selegiline + doxepin,
compared to control, versus the groups treated only with
doxepin.

Group

Figure 1. Immobilization time + SD in FST
after a single dose.
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Table 1. Immobilization time results in forced swimming test

Group

Figure 2. Immobilization time + SD in TST after 7
days of treatment.
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Table 2. Immobilization time results in tail suspension test after 7 days of treatment

Group III
(Doxepin
15mg/kg bw)

Group IV (Doxepin
10mg/kg bw +
Selegiline 2.5mg/kg
bw)

Group V
(Doxepin
15mg/kg bw +
Selegiline
5mg/kg bw)

Parameter

Group I
(Control)

Group II
(Doxepin
10mg/kg bw)

Normal
Distribution (D&P)

YES

YES

YES

YES

YES

M

151.8

120.7

111.4

109.3

72.08

SD

27.46

21.16

28.18

25.84

29.76

Variation (%) of
immobilization
time vs Control

-

-20.49%

-26.61%

-28%

-52.52%

**

***

ANOVA
Dunnett

p < 0.001
-

*

**

M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; * = statistically significant; ** =
statistically very significant; *** = statistically extremely significant.
.

Figure 3. The evaluation of the antidepressant effect in
TST after 7 days of treatment
In the immobilization test, after 7 days of treatment, the
antidepressant effect of the doxepin + selegiline
combination in high doses compared to control is more
potent than the single drug doxepin therapy, as is shown by
statistical significance.

Figure 4. Immobilization time + SD in TST after
14 days of treatment

Table 3. Immobilization time results in tail suspension test after 14 days of treatment
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Group III
(Doxepin
15mg/kg bw)

Group IV
(Doxepin
10mg/kg bw +
Selegiline
2.5mg/kg bw)

Group V (Doxepin
15mg/kg bw + Selegiline
5mg/kg bw)

Parameter

Group I
(Control)

Group II
(Doxepin
10mg/kg bw)

Normal
Distribution
(D&P)

YES

YES

YES

YES

YES

M

140.3

124.6

95.42

81.33

72.42

The antidepressant effect of associating doxepin and selegiline
SD

43.04

43.21

39.07

20.54

22.59

Variation (%) of
immobilization
time vs Control

-

-11.19%

-31.99%

-42.03%

-48.38%

***

***

ANOVA

p < 0.001

Dunnett

-

ns

*

M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; ns = statistically not significant; * =
statistically significant; *** = statistically extremely significant.

Figure 5. The evaluation of the antidepressant
effect in TST after 14 days of treatment
After a two-week treatment period, the effectiveness
of combining selegiline with doxepin intensifies in both
groups, while the group treated with a low doxepin dose
tends to become less effective compared to the control
group. The statistical significance of the immobilization
time decrease was noticeably stronger in the groups
treated with the two combined antidepressants.

Figure 6. Horizontal motor activity + SD after 7
days of treatment

2. Motor behavior
Table 4. Horizontal motor activity in 5 minutes after a 7-day treatment
Group III

Group IV
(Doxepin
10mg/kg bw +
Selegiline
2.5mg/kg bw)

Group V (Doxepin
15mg/kg bw + Selegiline
5mg/kg bw)

Parameter

Group I
(Control)

Group II
(Doxepin
10mg/kg bw)

Normal
Distribution
(D&P)

YES

YES

YES

YES

YES

M

405.4

354.7

318.8

465.1

495.5

SD

62.97

54.25

44.38

55.78

60.83

Variation (%) of
HMA vs Control

-

-12.5%

-21.36%

+16.1%

+17.56%

*

***

(Doxepin
15mg/kg bw)

ANOVA
Dunnett

p < 0.001
-

ns

**

M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; HMA = horizontal motor activity; ns =
statistically not significant; * = statistically significant; ** = statistically very significant; *** = statistically
extremely significant.
.
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Figure 7. Evolution of the horizontal motor
activity after one week compared to the control
group.

Figure 8. Evolution of the horizontal motor activity after
one week in the groups treated with the combination of
selegiline + doxepin versus groups treated only with
doxepin (*** - p<0.001 in t-Student test)

Table 5. Vertical motor activity in 5 minutes after a 7-day treatment

Parameter

Group I
(Control)

Group II
(Doxepin
10mg/kg bw)

Group III
(Doxepin
15mg/kg bw)

Group IV
(Doxepin
10mg/kg bw +
Selegiline
2.5mg/kg bw)

Group V
(Doxepin
15mg/kg bw +
Selegiline 5mg/kg
bw)

Normal
Distribution
YES
YES
YES
YES
YES
(D&P)
M
29.58
22.70
20.33
29.92
33.33
SD
9.07
6.717
6.401
10.77
13.3
Variation (%) of
-23.25%
-31.27%
+1.14%
+12.67%
VMA vs Control
ANOVA
p < 0.05
Dunnett
ns
ns
ns
ns
M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; VMA = vertical motor activity; ns =
statistically not significant.

Figure 9. Vertical motor activity + SD after 7 days
of treatment
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Figure 10. Evolution of the vertical motor activity after
one week compared to the control group

The antidepressant effect of associating doxepin and selegiline
.

After one week of treatment, both the horizontal and
the vertical motor activity decreases in the groups treated
only with doxepin in a dose-dependent manner, which was
expected due to its known sedative profile. However, this

phenomenon is completely annulled, even reversed, in a
statistically significant way (in case of HMA) for the
groups treated with the doxepin + selegiline combination
compared to the control group.

Table 6. Horizontal motor activity in 5 minutes after a 14-day treatment

Group III

Group IV
(Doxepin
10mg/kg bw +
Selegiline
2.5mg/kg bw)

Group V
(Doxepin
15mg/kg bw +
Selegiline
5mg/kg bw)

Parameter

Group I
(Control)

Group II
(Doxepin
10mg/kg bw)

(Doxepin
15mg/kg bw)

Normal
Distribution
(D&P)

YES

YES

YES

YES

YES

M

452.6

413.2

373.4

465.3

531.6

SD

70.97

80.98

73.31

70.31

77.02

Variation (%)
of HMA vs
Control

-

-8.71%

-17.5%

+2.81%

+17.45%

ns

*

ANOVA
Dunnett

p < 0.001
-

ns

*

M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; HMA = horizontal
motor activity; ns = statistically not significant; * = statistically significant.

Figure 11. Horizontal motor activity + SD after 14
days of treatment

Figure 12. Evolution of the horizontal motor activity
after two weeks compared to the control group
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Figure 13. Evolution of the horizontal motor
activity after two weeks in the groups treated
with the combination of selegiline + doxepin
versus groups treated only with doxepin (*** p<0.001 in t-Student test)

Figure 14. Vertical motor activity + SD after 14 days of
treatment

Table 7. Vertical motor activity in 5 minutes after a 14-day treatment
Group III

Group IV
(Doxepin
10mg/kg bw +
Selegiline
2.5mg/kg bw)

Group V
(Doxepin
15mg/kg bw +
Selegiline 5mg/kg
bw)

Parameter

Group I
(Control)

Group II
(Doxepin
10mg/kg bw)

Normal
Distribution
(D&P)

YES

YES

YES

YES

YES

M

51.73

47.33

40

63.50

73.82

SD

16.61

8.773

11.33

16.83

14.81

Variation (%) of
VMA vs Control

-

-8.51%

-22.68%

+22.75%

+42.7%

ns

**

ANOVA
Dunnett

(Doxepin
15mg/kg bw)

p < 0.001
-

ns

ns

M = average; SD = standard deviation; D&P = D`Agostino – Pearson test; VMA = vertical motor activity; ns =
statistically not significant; ** = statistically very significant.
After two weeks of treatment, the increase of HMA in
the groups treated with the selegiline + doxepin
combination compared to the control group is maintained,
although the statistical significance is lower than the one
registered after the first week of treatment. VMA
intensifies after 14 days of treatment in the same groups
compared to control, versus the 7-day determination. The
sedative effect of doxepin administered by itself decreases

Figure 15. Evolution of the vertical motor activity
after two weeks compared to the control group
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in the 2nd week compared to the first, which is consistent
with existing data in the scientific literature regarding the
use of doxepin in long time treatments.

The antidepressant effect of associating doxepin and selegiline

Conclusions
Selegiline in association with doxepin induced a slight
reduction in the immobilization time, compared to doxepin
administered alone, in FST after the acute treatment.
After a 7-day treatment, the most intense antidepressant effect compared to the control group was
registered in the groups treated with doxepin 10 mg/kg bw
+ selegiline 2.5 mg/kg bw (-28%; p<0.01) and doxepin 15
mg/kg bw + selegiline 5 mg/kg bw (-52.52%; p<0.001).
Comparing the single drug doxepin therapy with the
combined doxepin + selegiline therapy, the antidepressant
effect almost doubled when using the combination in
higher dosages.
After a 14-day treatment, the most intense
antidepressant effect compared to the control group
continued to register in the groups treated with doxepin 10
mg/kg bw + selegiline 2.5 mg/kg bw (-42.03%; p<0.001)
and doxepin 15 mg/kg bw + selegiline 5 mg/kg bw (48.38%; p<0.001). Comparing the single drug doxepin
therapy with the combined doxepin + selegiline therapy,
the combination of the two antidepressants continued to be
more effective, although the difference in intensity
between the effect of the single drug therapy and that of the
double drug therapy decreased, especially in the case of
higher dosages.
Assessing the motor activity registered after 7 and 14
days of treatment, selegiline not only canceled the sedative
effect of doxepin, but to some extent, reversed it. This
phenomenon is more obvious and significant in HMA than
in VMA.
Based on our analysis, we conclude that a selegiline +
doxepin combination therapy not only significantly
increases the antidepressant effect, but also prevents the
sedative side effect of doxepin administered as a single
drug therapy.
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